Antibody · HER2+ 유방암

11개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved11 programs
AntibodyCurated CoreFDABeOne MedicinesApproved

tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr)

Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 213Status Approved
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, HER2, pyrotinib + pertuzumab/trastuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#SalivaryGlandCarcinoma+2
Trials 30Status Recruiting
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 3

trastuzumab (Herceptin, Endocrine therapy combined with trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#monoclonal-antibody#Sun
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Neoadjuvant chemotherapy combined with Toripalimab (Neoadjuvant chemotherapy combined with Toripalimab)

TNBC, Triple Negative Breast Cancer · TNBC, Triple Negative Breast Cancer

#TNBCTripleNegativeBreastCancer#Antibody#Phase2#monoclonal-antibody#TNBC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab)

HR Positive/HER2 Low Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HRPositive+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab + trastuzumab + metronomic chemotherapy)

Elderly Metastatic Breast Cancer Population · Elderly Metastatic Breast Cancer Populat

#ElderlyMetastaticBreastCancerPop#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleFujian Medical University Union…Phase 2

trastuzumab (Herceptin, Pyrotinib+Trastuzumab+Capecitabine)

Breast Cancer; Adjuvant Therapy · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#AdjuvantTherapy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleNanlin LiPreclinical

trastuzumab (Herceptin, TP Chemotherapy + Trastuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleNanlin LiPreclinical

trastuzumab (Herceptin, TP Chemotherapy + Trastuzumab + Pertuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

Tremelimumab monotherapy (Tremelimumab monotherapy)

Urothelial Bladder Cancer; Triple-negative Breast Cancer · Urothelial Bladder Cancer

#UrothelialBladderCancer#Antibody#Phase2#monoclonal-antibody#Triple-negativeBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy)

HER2-positive Breast Cancer; Neoadjuvant Therapy · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HER2-positiveBreastCancer+2
Trials 1Status Recruiting